TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.

Somatic mutations and copy number alterations (as a result of deletion or amplification of large portions of a chromosome) are major drivers of human lung cancers. Detailed analysis of lung cancer-associated chromosomal amplifications could identify novel oncogenes. By performing an integrative cytogenetic and gene expression analysis of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) cell lines and tumors, we report here the identification of a frequently recurring amplification at chromosome 11 band p13. Within this region, only TNF receptor-associated factor 6 (TRAF6) exhibited concomitant mRNA overexpression and gene amplification in lung cancers. Inhibition of TRAF6 in human lung cancer cell lines suppressed NF-κB activation, anchorage-independent growth, and tumor formation. In these lung cancer cell lines, RAS required TRAF6 for its oncogenic capabilities. Furthermore, TRAF6 overexpression in NIH3T3 cells resulted in NF-κB activation, anchorage-independent growth, and tumor formation. Our findings show that TRAF6 is an oncogene that is important for RAS-mediated oncogenesis and provide a mechanistic explanation for the previously apparent importance of constitutive NF-κB activation in RAS-driven lung cancers.

[1]  C. Paweletz,et al.  A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors , 2010, BMC Medical Genomics.

[2]  A. Baldwin,et al.  Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. , 2010, Cancer research.

[3]  Yeul-Hong Kim,et al.  Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. , 2010, Cancer genetics and cytogenetics.

[4]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[5]  Ryan D. Morin,et al.  Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype , 2010, Nature Medicine.

[6]  D. Feldser,et al.  Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.

[7]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[8]  Elizabeth E. Molnar,et al.  TRAF6 Autoubiquitination-Independent Activation of the NFκB and MAPK Pathways in Response to IL-1 and RANKL , 2008, PloS one.

[9]  Bradley P. Coe,et al.  Integrative genomic and gene expression analysis of chromosome 7 identified novel oncogene loci in non-small cell lung cancer. , 2008, Genome.

[10]  A. Telenius,et al.  High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. , 2008, Blood.

[11]  Calum MacAulay,et al.  SIGMA2: A system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes , 2008, BMC Bioinformatics.

[12]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[13]  Dafydd G. Thomas,et al.  Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. , 2008, Cancer research.

[14]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[15]  B. Coe,et al.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.

[16]  J. Flores,et al.  The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.

[17]  Lin Ji,et al.  A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras , 2008, Molecular Cancer Therapeutics.

[18]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[19]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[20]  A. Karsan,et al.  Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. , 2007, The Journal of experimental medicine.

[21]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[22]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[23]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[24]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[25]  K. Robertson,et al.  Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer , 2007, Oncogene.

[26]  Carolyn J. Brown,et al.  A comprehensive analysis of common copy-number variations in the human genome. , 2007, American journal of human genetics.

[27]  Bharat B. Aggarwal,et al.  Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions , 2006 .

[28]  J. Minna,et al.  Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. , 2006, Cancer cell.

[29]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[30]  Calum MacAulay,et al.  Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small‐cell lung cancer cell lines , 2006, Genes, chromosomes & cancer.

[31]  A. Hoffmann,et al.  Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras , 2005, Oncogene.

[32]  M. Meyerson,et al.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. , 2005, Cancer research.

[33]  R. Siebert,et al.  CD95 and TRAF2 promote invasiveness of pancreatic cancer cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Elena Marchiori,et al.  Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..

[35]  Bradley P. Coe,et al.  A tiling resolution DNA microarray with complete coverage of the human genome , 2004, Nature Genetics.

[36]  A. Rao.  Faculty Opinions recommendation of CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. , 2003 .

[37]  A. Ashworth,et al.  CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members , 2003, Nature.

[38]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[39]  L. Hood,et al.  Activated Notch4 Inhibits Angiogenesis: Role of β1-Integrin Activation , 2002, Molecular and Cellular Biology.

[40]  Young Chul Park,et al.  All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. , 2002, Journal of cell science.

[41]  R. Gascoyne,et al.  TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies , 2000, The Journal of Immunology.

[42]  A. Ashworth,et al.  Identification of the familial cylindromatosis tumour-suppressor gene , 2000, Nature Genetics.

[43]  R. Weinberg,et al.  Analysis of viral and somatic activations of the cHa-ras gene , 1985, Journal of virology.